A phase I and pharmacologic study of the MDR converter GF120918 in combination with doxorubicin in patients with advanced solid tumors

BackgroundResistance to chemotherapy can partly be explained by the activity of membrane bound P-glycoprotein. Competitive inhibition of P-glycoprotein, by multidrug resistance (MDR) converters, may overcome this MDR. Previously studied MDR converters either have serious intrinsic side effects or considerably influence the pharmacokinetics of cytotoxic agents at concentrations theoretically required to convert MDR. GF120918 is a third-generation MDR converter with high affinity for P-glycoprotein and can be given orally. We performed a phase 1 study with escalating doses of GF120918 in combination with doxorubicin.Patients and methodsThe study group comprised 46 patients with advanced solid tumors. Doxorubicin was administered on day 1 (cycle 1), GF120918 on days 22–24 (cycle 2), and on days 29–33 with doxorubicin administered on day 31 (cycle 3). Pharmacokinetics of both GF120918 and doxorubicin were studied. The starting daily dose of GF120918 was 50 mg and was to be increased in subsequent cohorts until a steady state plasma level of 100 ng/ml was reached. The starting dose of doxorubicin was 50 mg/m2 and was to be increased after reaching the target dose level of GF120918.ResultsIn 37 of the 46 patients, full pharmacokinetic data from the three scheduled cycles were obtained. Pharmacokinetics of GF120918 showed a less than linear increase in C max with increasing doses, with considerable interpatient variation. The target steady-state plasma level for GF120918 was exceeded in 12 out of 19 patients who received 400 mg GF120918 alone twice daily and in 12 of 17 patients who received 400 mg GF120918 twice daily in combination with doxorubicin. GF120918 pharmacokinetics were not influenced by coadministration of doxorubicin. The doxorubicin AUC was only marginally influenced by GF120918 and only at the highest dose levels. In these patients there was a significant increase in the AUC of doxorubicinol in cycle 3 as compared to cycle 1. Hematologic toxicity mainly consisted of neutropenia and was more severe in cycle 3 than in cycle 1 (13 vs 5 patients with grade 4 neutropenia, P=0.003). Neutropenic fever was the dose-limiting toxicity at a doxorubicin dose of 75 mg/m2 with 400 mg GF120918 twice daily. The toxicity of GF120918 was limited to somnolence in eight patients and occasional gastrointestinal complaints.ConclusionGF120918 is an MDR converter with only minimal side effects at a dose level yielding concentrations able to convert the action of P-glycoprotein in vitro. A doxorubicin dose of 60 mg/m2 on day 3 in combination with 400 mg GF120918 twice daily on days 1–5 is an acceptable regimen for further clinical trials.

[1]  I. Pastan,et al.  Multiple-drug resistance in human cancer. , 1987, The New England journal of medicine.

[2]  Y. Ostchega,et al.  Verapamil and adriamycin in the treatment of drug-resistant ovarian cancer patients. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  P. Meltzer,et al.  Drug-resistance in multiple myeloma and non-Hodgkin's lymphoma: detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  I. Pastan,et al.  Clinical trials of agents that reverse multidrug-resistance. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  J. M. Ford,et al.  Pharmacology of drugs that alter multidrug resistance in cancer. , 1990, Pharmacological reviews.

[6]  C. Seynaeve,et al.  A phase II study of epidoxorubicin in colorectal cancer and the use of cyclosporin-A in an attempt to reverse multidrug resistance. , 1991, British Journal of Cancer.

[7]  H. Herweijer,et al.  Multidrug resistance (mdr) genes in human cancer. , 1991, British Journal of Cancer.

[8]  V. Ferrans,et al.  ICRF-187 permits longer treatment with doxorubicin in women with breast cancer. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  B. Chauffert,et al.  Feasibility of using quinine, a potential multidrug resistance-reversing agent, in combination with mitoxantrone and cytarabine for the treatment of acute leukemia. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  B. Sikic,et al.  Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a phase I trial to modulate multidrug resistance. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  P. Sonneveld,et al.  Modulation of multidrug-resistant multiple myeloma by cyclosporin , 1992, The Lancet.

[12]  T. Tsuruo,et al.  Clinical significance of multidrug resistance P-glycoprotein expression on acute nonlymphoblastic leukemia cells at diagnosis. , 1992, Blood.

[13]  C. Vergely,et al.  In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative. , 1993, Cancer research.

[14]  W. Scheithauer,et al.  Clinical trials of agents that reverse multidrug resistance. A literature review , 1993, Cancer.

[15]  I. Pastan,et al.  Biochemistry of multidrug resistance mediated by the multidrug transporter. , 1993, Annual review of biochemistry.

[16]  B. Sikic,et al.  Phase I trial of doxorubicin with cyclosporine as a modulator of multidrug resistance. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  P. Sonneveld,et al.  Clinical relevance of P-glycoprotein expression in haematological malignancies. , 1994, Leukemia research.

[18]  D. Kerr,et al.  Quinidine as a resistance modulator of epirubicin in advanced breast cancer: mature results of a placebo-controlled randomized trial. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  A. Caraceni,et al.  Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  A. Cowman,et al.  Rapid up-regulation of mdr1 expression by anthracyclines in a classical multidrug-resistant cell line. , 1995, British Journal of Cancer.

[21]  P. Picci,et al.  Expression of P-glycoprotein in high-grade osteosarcomas in relation to clinical outcome. , 1995, The New England journal of medicine.

[22]  A. Cavaliere,et al.  Secondary alcohol metabolites mediate iron delocalization in cytosolic fractions of myocardial biopsies exposed to anticancer anthracyclines. Novel linkage between anthracycline metabolism and iron-induced cardiotoxicity. , 1995, The Journal of clinical investigation.

[23]  F. Ognibene,et al.  Phase I crossover study of paclitaxel with r-verapamil in patients with metastatic breast cancer. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  U. Germann,et al.  P-glycoprotein--a mediator of multidrug resistance in tumour cells. , 1996, European journal of cancer.

[25]  T. L. Lloyd,et al.  Flow cytometric assay of modulation of P-glycoprotein function in whole blood by the multidrug resistance inhibitor GG918. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[26]  C. Bolliger,et al.  Evaluation of newer prognostic markers for adult soft tissue sarcomas. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  S. Swain,et al.  Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  G. Giaccone,et al.  A dose-finding and pharmacokinetic study of reversal of multidrug resistance with SDZ PSC 833 in combination with doxorubicin in patients with solid tumors. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[29]  R. Stupp,et al.  Ventricular arrhythmia and torsade de pointe: dose limiting toxicities of the MDR-modulator S9788 in a phase I trial. , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

[30]  J. Verweij,et al.  Determination of doxorubicin and doxorubicinol in plasma of cancer patients by high-performance liquid chromatography. , 1999, Analytical Biochemistry.

[31]  J Verweij,et al.  Clinical pharmacokinetics of doxorubicin in combination with GF120918, a potent inhibitor of MDR1 P-glycoprotein. , 1999, Anti-cancer drugs.

[32]  J. Beijnen,et al.  Increased accumulation of doxorubicin and doxorubicinol in cardiac tissue of mice lacking mdr1a P-glycoprotein , 1999, British Journal of Cancer.

[33]  T. Grogan,et al.  Phase I/II study of the P-glycoprotein modulator PSC 833 in patients with acute myeloid leukemia. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  C. Slapak,et al.  A Phase I Trial of a Potent P-Glycoprotein Inhibitor, Zosuquidar Trihydrochloride (LY335979), Administered Intravenously in Combination with Doxorubicin in Patients with Advanced Malignancy , 2004, Clinical Cancer Research.

[35]  D. Kerr,et al.  The effect of verapamil on the pharmacokinetics of adriamycin , 2004, Cancer Chemotherapy and Pharmacology.

[36]  M. Zucchetti,et al.  Changes in doxorubicin distribution and toxicity in mice pretreated with the cyclosporin analogue SDZ PSC 833 , 1995, Cancer Chemotherapy and Pharmacology.